In 1997, ACCESS, a national continuing medical education (CME) program on psychosis management for primary care physicians, was delivered (2) . The needs assessment identified GPs' perceived lack of access to, and collaboration with, psychiatrists as a primary clinical and (or) educational need. The program's educational design attempted to address this need. Groups of 8 to 10 GPs and a psychiatrist consultant facilitator were formed. They met locally in their communities for 2 separate case-based educational sessions. Between sessions, the GPs had telephone access to their psychiatrist consultant. This was included as part of the educational program to foster collaboration and access to psychiatrists, to specifically meet the identified need. Funding for psychiatrist availability was provided. Telephone logbooks for documentation were developed, and interactions were tracked. However, the telephone contacts were rarely if ever used. Most psychiatrists received no calls from the GPs.
A second clinical experience demonstrated a similar unexpected outcome (3). In 1996, GPs at North York General Hospital expressed dissatisfaction and frustration with a poor, noncollaborative relationship and a lack of access to psychiatry. In response, the hospital department of psychiatry implemented a Primary Care Psychiatric Outreach Program. If requested by the GP, a psychiatrist would provide timely on-site collaborative clinical educational consultations in the GP's office. This almost immediately satisfied the GP outcry for improved access and markedly improved the psychiatry-family practice department relations. Still, the Primary Care Psychiatric Outreach Program was and continues to be rarely, if ever, used. Despite having 381 GPs on staff at our hospital, we average 1 or 2 requests each month from the same few physicians. Meanwhile, our traditional outpatient clinic remains extremely busy, with approximately 120 new GP referrals each month.
Models of collaborative and shared mental health care have many proposed benefits (4). Our benevolent, liberal-minded sentiments toward collaborative care had us hopeful that collaboration would be eagerly embraced and appreciated. In hindsight, this was a naïve, overly simplistic vision for mental health delivery. The survey by Lucena and others demonstrates that issues of collaborative care are more complex. Many practitioners are uninterested in close collaboration, including GPs. Lucena and others' work adds important information at a time when delivery systems and third-party payers are struggling with ways to better provide mental health care to their populations.
Thomas E Ungar, MD, MEd, CCFP, FRCPC, ABPN Toronto, Ontario
Reply to Dr Ungar
Dear Editor:
We are happy that our work can help the effort to increase shared mental health care. First, it is important to bear in mind that only some GPs and psychiatrists are ready to engage in on-site collaboration. Dr Ungar's experiences validate the results of our survey: closer schemes of collaboration tend to involve only a few physicians. They are far from being the most accepted model of clinical practice for GPs and psychiatrists. For example, Dr Ungar stated that, of 381 GPs at North York General Hospital, only a few physicians request closer collaboration. Most GPs still rely on referral to the psychiatric outpatient clinic as the main approach to psychiatric patients.
Our survey indicates that strategies focusing on telephone access may be more fruitful. The failure of the ACCESS project may relate to the fact that psychosis management deals with a disorder rare in general practice, compared with common disorders such as depression, anxiety, substance abuse, or somatoform disorders. New efforts may be more productive if they concentrate on the latter disorders first.
Ricardo Lucena MD, MSc, PhD Alain Lesage MD, MPhil Montréal, Québec

Fungal Dermatitis with Olanzapine in Schizophrenia
Premarketing studies of olanzapine found a 2% incidence of fungal dermatitis vs 0% with placebo (1). To our knowledge, there are no other published reports of olanzapine fungal dermatitis. We report a patient with schizophrenia who developed fungal dermatitis soon after starting olanzapine.
Case Report
Mr A, age 24 years, was recently diagnosed with DSM-IV schizophrenia, paranoid type. His psychiatric history included 2 brief admissions for psychosis in other hospital centres. On both occasions, the patient stopped taking his medication immediately after discharge. Medical history, including a history of dermatologic disease, was otherwise negative. At the time of presentation to our hospital centre, Mr A denied using any psychiatric medication for 4 years. He initially received 1 dose of haloperidol for agitation and began olanzapine 20 mg daily, with lorazepam 1 mg daily, as needed. A physical examination revealed no physical abnormalities, including no dermatologic abnormalities.
Two weeks after beginning olanzapine, Mr A noticed a new, pale tan, circular, scaly, mildly pruritic patch on the anterior of his right shoulder. Three weeks later, the dermatologic abnormality persisted, and dermatology was consulted. The dermatologist confirmed the diagnosis of a fungal dermatitis, tinea versicolor, and prescribed topical ketoconazole cream. The infection appeared to be improving after several weeks. The patient was discharged but was noncompliant with follow-up.
Discussion
Tinea versicolor, a superficial mycosis, is caused by several of the species of the genus, Malassezia (2). It occurs primarily in the tropics but is not rare in North America (2) . Other reported dermatologic adverse effects of olanzapine include vesiculobullous eruption, pruritus, and peripheral edema (3) . Although other antipsychotic agents have been associated with various dermatologic manifestations-including exanthems, pruritus, photosensitivity, angioedema, exfolliative dermatitis, and cellulitis-none except for ziprasidone have reported occurrences of fungal dermatitis linked with their use (3) . In this otherwise healthy patient with a negative history of fungal dermatitis, the infection arose 2 weeks after the initiation of pharmacotherapy, which supported the strength of this association. Resolution of the dermatitis after antifungal treatment, despite continuing olanzapine, makes it difficult to be certain about the causal nature of this relation. Nevertheless, physicians should be sensitive to the possibility of fungal dermatitis as a complication of olanzapine pharmacotherapy.
Re: Canadian Psychiatric Inpatient Religious Commitment
Dr Watters is somewhat disingenuous in using his "critique" (1) of the study by Baetz and others (2) to advocate his well-known view of "religion as the most destructive of human inventions." The search for finding meaning and guidance about life and death has been around for thousands of years and can hardly be described as an "invention." It has been expressed in what we choose to call "religion" in many ways that have changed over time but are present in all cultures. These philosophical considerations, however, were not the issue in the paper by Baetz and others.
Their study is welcome. It attempts to bridge the gap between 2 aspects of human behaviour that are frequently seen in isolation: psychopathology and religious observance. They also admit to the limitations of their investigation. One could add that answers to 3 questions on a Gallup Poll (3) can only provide a simplistic view of an individual's belief system. Moreover, religious commitment seemed restricted to adherence to the Christian religion, perhaps inevitable in the demographic distribution of the study population. Similarly, length of stay in hospital is, at best, a rough indication of clinical status.
Nevertheless, the paper by Baetz and others is a welcome start, and a more detailed investigation into the relation between overt psychopathology and religious beliefs and practices could lead to useful dialogue and enhancement of our therapeutic armamentarium.
